证券代码：872925 证券简称：锦好医疗 公告编号：2025-044 惠州市锦好医疗科技股份有限公司 关于召开 2025 年第一次临时股东会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东会届次 本次会议为 2025 年第一次临时股东会。 （二）召集人 本次股东会的召集人为董事会。 2025 年 5 月 12 日，公司召开第三届董事会第十一次会议审议通过《关于提 请召开 2025 年第一次临时股东会的议案》。 （三）会议召开的合法合规性 本次股东会的召集符合《公司法》等有关法律、法规及《公司章程》的规定， 无需相关部门批准或履行其他程序。 （四）会议召开方式 本次会议采用现场投票、网络投票和其他投票方式相结合方式召开。 公司股东应选择现场投票、网络投票中的一种方式，如果同一表决权出现 重复投票表决的，以第一次投票表决结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2025 年 5 月 29 日 15:00。 2、网络投票起止时间：2 ...

法律意见书 北京大成（广州）律师事务所 关于惠州市锦好医疗科技股份有限公司 2025 年限制性股票激励计划（草案）的 法律意见书 www.dentons.com 广州市天河区珠江东路 6 号广州周大福金融中心 14 层、15 层 电话：+86 20 8527 7000 传真：+86 20 8527 7002 二〇二 五 年 五 月 目 录 | 一、公司实行股权激励计划的条件 5 | | --- | | 二、本次股权激励计划的主要内容 6 | | 三、本次股权激励计划涉及的法定程序 13 | | 四、本次股权激励计划激励对象的确定 15 | | 五、本次股权激励计划的信息披露 15 | | 六、公司没有为激励对象提供财务资助 15 | | 七、本次股权激励计划不存在明显损害上市公司及股东利益的情形 15 | | 八、本次股权激励计划存在需要关联董事回避表决的情形 16 | | 九、结论意见 16 | 法律意见书 法律意见书 致：惠州市锦好医疗科技股份有限公司 北京大成（广州）律师事务所（以下简称"本所"）接受惠州市锦好医疗科 技股份有限公司（以下简称"锦好医疗"或者"公司"）的委托，担任锦好医疗 实施 2025 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2025-039 惠州市锦好医疗科技股份有限公司 第三届董事会第十一次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 5 月 12 日 2.会议召开地点：公司会议室 3.会议召开方式：现场与通讯方式相结合 4.发出董事会会议通知的时间和方式：2025 年 5 月 9 日以书面方式发出 5.会议主持人：王敏先生 6.会议列席人员：监事及高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开程序符合《公司法》、《公司章程》和《董事会议事规 则》的相关规定。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事李忠轩因工作原因以通讯方式参与表决。 董事郑能恒因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于<惠州市锦好医疗科技股份有限公司 2025 年限制性股票激 励计划（草案）>的议案》 1.议案内容 ...

Investment Rating - The report maintains a "Recommended" rating for the healthcare industry [6] Core Insights - The pharmaceutical sector has shown a slight underperformance compared to the CSI 300 index, with a 1.50% increase from April 28 to May 9, 2025, lagging by 0.06 percentage points [2][11] - Year-to-date, the pharmaceutical index has risen by 1.19%, outperforming the CSI 300 by 3.45 percentage points [13] - As of May 9, 2025, the valuation of the pharmaceutical sector stands at 26.54 times (TTM), with a premium of 141.81% over the CSI 300 [16] Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 28 to May 9, 2025, was a 1.50% increase, ranking 16th among 31 industry indices [2][11] - The year-to-date performance shows a 1.19% increase, ranking 15th among the indices [13] 2. Key Company Announcements - Notable companies such as Kellytai, BGI Genomics, and Dongfang Bio have reported varying financial results, with some showing declines in net profit [21] 3. Industry Perspective - The pharmaceutical sector's revenue decreased by 0.99% in 2024, with net profit down by 12.97%. In Q1 2025, revenue fell by 4.78%, and net profit decreased by 12.21% [4][22] - The report highlights a shift in market focus from earnings to fundamental changes in the industry and companies, with optimism surrounding innovative drugs, international expansion, and the clearing of centralized procurement impacts [4][22] - The report suggests that the innovative drug sector is entering a phase of realization of results, with significant R&D progress and minimal impact from trade wars, making it a key investment theme for 2025 [4][22] 4. Stock Performance - The top-performing stocks included Changshan Pharmaceutical (+26.29%) and Haichuang Pharmaceutical (+25.85%), while the worst performers included Puli Retreat (-69.88%) and ST Suwu (-31.39%) [3][20]

Investment Rating - The report maintains a "Recommended" rating for the healthcare sector [6]. Core Insights - The pharmaceutical sector has shown a slight underperformance compared to the CSI 300 index, with a 1.50% increase from April 28 to May 9, 2025, lagging by 0.06 percentage points [2][11]. - Year-to-date, the pharmaceutical index has risen by 1.19%, outperforming the CSI 300 by 3.45 percentage points [13]. - As of May 9, 2025, the valuation of the pharmaceutical sector stands at 26.54 times (TTM), with a premium of 141.81% over the CSI 300 [16]. Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 28 to May 9, 2025, was a 1.50% increase, ranking 16th among 31 sectors [2][11]. - The year-to-date performance shows a 1.19% increase, ranking 15th among the sectors [13]. 2. Key Company Announcements - Key companies such as Kelly Tai, BGI Genomics, and Dongfang Bio reported varying financial results, with some showing significant declines in net profit [21]. 3. Industry Perspective - The pharmaceutical sector's revenue decreased by 0.99% in 2024, with net profit down by 12.97%. In Q1 2025, revenue fell by 4.78%, and net profit decreased by 12.21% [4][22]. - The report highlights a shift in market focus from earnings to fundamental changes in the industry and companies, with optimism surrounding innovative drugs, international expansion, and the clearing of centralized procurement impacts [4][22]. - The report suggests that the innovative drug sector is entering a phase of realization, with significant R&D progress and minimal impact from trade wars, making it a key investment theme for 2025 [4][22]. 4. Stock Performance - The top-performing stocks included Changshan Pharmaceutical (+26.29%), Haichuang Pharmaceutical (+25.85%), and Jinhao Medical (+25.32%) [3][20]. - Conversely, the worst performers included Puli Retreat (-69.88%) and ST Suwu (-31.39%) [3][20].

融资余额增幅前20只个股中，从市场表现来看，平均上涨3.23%，涨幅居前的有鑫磊股份、七丰精工、 航天南湖，涨幅分别为19.82%、17.45%、11.11%。跌幅居前的有久祺股份、九菱科技、锦好医疗，跌 幅分别为10.95%、7.37%、5.99%。 5月9日沪指下跌0.30%，市场两融余额为18040.11亿元，较前一交易日减少47.44亿元。 证券时报·数据宝统计显示，截至5月9日，沪市两融余额9172.12亿元，较前一交易日减少19.32亿元；深 市两融余额8816.27亿元，较前一交易日减少27.34亿元；北交所两融余额51.72亿元，较前一交易日减少 0.78亿元；深沪北两融余额合计18040.11亿元，较前一交易日减少47.44亿元。 分行业看，申万所属行业中，融资余额增加的行业有7个，增加金额最多的行业是国防军工，融资余额 增加4.03亿元；其次是传媒、房地产行业，融资余额分别增加1.65亿元、0.79亿元。 具体到个股来看，融资余额出现增长的股票有1591只，占比43.35%，其中，226股融资余额增幅超过5% 。融资余额增幅最大的是鑫磊股份，该股最新融资余额7159.36万元，较前一交易日 ...

中信建投证券股份有限公司 关于惠州市锦好医疗科技股份有限公司 向不特定合格投资者公开发行股票之保荐工作总结报告书 中信建投证券股份有限公司（以下简称"中信建投"或"保荐机构"）作为 惠州市锦好医疗科技股份有限公司（以下简称"锦好医疗"、"公司"或"发行 人"）向不特定合格投资者公开发行股票（以下简称"本次发行"）的保荐机构， 履行持续督导职责期限至 2024 年 12 月 31 日。目前，本次发行持续督导期限已 经届满，根据《证券发行上市保荐业务管理办法》《北京证券交易所证券发行上 市保荐业务管理细则》《北京证券交易所股票上市规则》等法规和规范性文件要 求，保荐机构出具本保荐工作总结报告书。 二、保荐工作概述 （一）尽职推荐工作 发行人名称 惠州市锦好医疗科技股份有限公司 证券代码 872925 注册资本 9,768.6643 万元 注册地址 惠州仲恺高新区四环南路（惠环段）207 号锦好智慧医疗产业 园 主要办公地址 惠州仲恺高新区四环南路（惠环段）207 号锦好智慧医疗产业 园 法定代表人 王敏 实际控制人 王敏、王芳 联系电话 0752-3266781 本次证券发行类型 向不特定合格投资者公开发行股票并 ...

Market Overview - The Shanghai Composite Index closed at 3328.43 points, above the six-month moving average, with an increase of 0.37% [1] - The total trading volume of A-shares reached 12152.25 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 144 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - JinHao Medical: 26.73% - SuAo Sensor: 19.75% - HuaWu Co., Ltd.: 17.98% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Aerospace Intelligent Manufacturing - Changqing Technology - China Merchants Highway [1] Performance of Selected Stocks - JinHao Medical: Today's increase of 29.96% with a turnover rate of 23.69% [1] - SuAo Sensor: Increased by 20.05% with a turnover rate of 8.96% [1] - HuaWu Co., Ltd.: Increased by 19.94% with a turnover rate of 20.89% [1] Additional Notable Stocks - Other stocks with notable performance include: - JiuDing Investment: 9.97% increase, 7.73% turnover rate - Arrow Home: 10.02% increase, 8.27% turnover rate - Construction Industry: 10.01% increase, 13.40% turnover rate [1]

Stock Performance - Several stocks have shown significant gains, with notable performances including: - 恒天海龙 with a 10.07% increase over two days [2] - 晨曦航空 achieving a 19.96% rise on its first board [3] - 通易航天 with a remarkable 29.96% increase on its first board [3] - 新坐标 maintaining a 10.01% increase over four days [5] - 全筑股份 also showing a 10.00% increase over four days [9] Industry Trends - The robotics sector is gaining traction, with multiple companies experiencing stock price increases attributed to advancements in robotic technology and applications [4][5][7] - The AI computing industry is showing strong performance, as indicated by the positive financial results from companies in this sector, suggesting a sustained high level of industry activity [8] - The brain-computer interface (BCI) technology is gaining attention following FDA approval for Neuralink's device, which is aimed at aiding patients with severe communication disabilities [11] - The chemical industry is experiencing volatility in product prices, drawing market interest towards related companies [13] - The semiconductor industry is benefiting from increased investment and support for domestic high-end lithography machines, which is expected to boost the semiconductor equipment supply chain [16] - The real estate sector is reacting positively to the People's Bank of China's decision to lower housing loan interest rates, which is likely to stimulate market activity [18] Market Reactions - Stocks related to the ride-hailing industry are responding positively to the news of a partnership between autonomous driving company 小马智行 and Uber, with significant stock price increases observed [20][21] - The food and beverage sector is also seeing positive movements, influenced by the central bank's announcement of a new loan program aimed at boosting consumer spending [22][24] - The financial sector is reacting to the People's Bank of China's announcement of a series of monetary policy measures, including a reserve requirement ratio cut and interest rate adjustments [25][26]

Core Viewpoint - The medical device sector experienced a significant rally, with notable stocks such as JinHao Medical hitting the daily limit increase, while LuDe Medical and AiPeng Medical rose over 7% [1] Group 1: Stock Performance - JinHao Medical reached a daily limit increase of 30% [1] - LuDe Medical and AiPeng Medical saw increases exceeding 7% [1] - Other companies like YiRui Biological, WeiSi Medical, and KangTuo Medical also experienced upward movement [1] Group 2: Market Activity - There is a notable influx of dark pool capital into these stocks, indicating potential investor interest and market activity [1]